PTGX

#1031

Protagonist Therapeutics, Inc

92.0800

+6.88%

Сектор:

Базовая:

Валюта прибыли:

Дневной диапазон

Годовой диапазон

Дневное изменение

+6.88%

Месячное изменение

+11.68%

6-месячное изменение

+22.56%

Годовое изменение

+22.56%

Предыдущее закрытие

86.1500

Open

92.2100

Bid

Ask

Low

92.0800

High

92.2200

Объем

152

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities 72.48 M107.86 M108.14 M70.24 M184.15 M57.67 M 57.67 M Cash from investing activities 90.97 M15.86 M91.47 M39.26 M299.48 M49.33 M 49.33 M Cash from financing activities 247.63 M129.92 M18.84 M170.48 M25.85 M22.86 M 22.86 M Free cash flow 72.01 M106.76 M107.34 M69.63 M182.8 M56.08 M 56.08 M

PTGX

Financials

Новости

Protagonist Therapeutics: доходы, прибыль оказались ниже прогнозов в Q4

Protagonist Therapeutics earnings missed by $0.35, revenue fell short of estimates

Citizens raises Protagonist Therapeutics stock price target on drug approvals

Директор Protagonist Therapeutics Уильямс продал акции на $1,48 млн

Protagonist Therapeutics director Williams sells $1.48 million in shares

Директор Protagonist Therapeutics продает акции на $1,67 млн

Protagonist Therapeutics director sells $1.67 million in shares

Топ биотехнологических акций 2026 года по версии Truist

Top Biotech Stocks to Watch in 2026, According to Truist

H.C. Wainwright повысил целевую цену акций Protagonist до $117

Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright

Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)